Insider Selling: Alphatec (NASDAQ:ATEC) EVP Sells $1,132,600.00 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 70,000 shares of the firm’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $16.18, for a total transaction of $1,132,600.00. Following the sale, the executive vice president directly owned 461,861 shares of the company’s stock, valued at $7,472,910.98. This trade represents a 13.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

David Sponsel also recently made the following trade(s):

• On Friday, September 19th, David Sponsel sold 2,555 shares of Alphatec stock. The stock was sold at an average price of $15.34, for a total transaction of $39,193.70.
• On Thursday, September 18th, David Sponsel sold 137,445 shares of Alphatec stock. The stock was sold at an average price of $15.09, for a total transaction of $2,074,045.05.

Alphatec Trading Down 1.0%

NASDAQ:ATEC opened at $16.33 on Friday. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. Alphatec Holdings, Inc. has a 12 month low of $6.97 and a 12 month high of $17.15. The company has a market cap of $2.42 billion, a PE ratio of -14.45 and a beta of 1.05. The company has a 50 day simple moving average of $15.22 and a two-hundred day simple moving average of $13.19.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. The business had revenue of $196.50 million for the quarter, compared to the consensus estimate of $182.78 million. During the same period in the previous year, the firm earned ($0.28) EPS. The company’s revenue was up 30.4% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. Research analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ATEC. Barclays reissued an “overweight” rating and set a $22.00 price objective (up previously from $21.00) on shares of Alphatec in a research report on Monday, August 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alphatec in a report on Tuesday, October 14th. JPMorgan Chase & Co. started coverage on shares of Alphatec in a report on Friday, October 24th. They issued an “overweight” rating and a $19.00 target price for the company. Stifel Nicolaus started coverage on shares of Alphatec in a report on Tuesday. They issued a “buy” rating and a $20.00 target price for the company. Finally, Wells Fargo & Company upped their target price on shares of Alphatec from $14.00 to $16.00 and gave the stock an “overweight” rating in a report on Thursday, October 16th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $18.44.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ATEC. Nuveen LLC bought a new position in shares of Alphatec during the 1st quarter valued at approximately $135,874,000. Granite Investment Partners LLC boosted its position in shares of Alphatec by 320.6% during the 2nd quarter. Granite Investment Partners LLC now owns 1,720,944 shares of the medical technology company’s stock valued at $19,102,000 after acquiring an additional 1,311,748 shares during the last quarter. MetLife Investment Management LLC raised its position in shares of Alphatec by 1,818.5% during the 1st quarter. MetLife Investment Management LLC now owns 1,213,943 shares of the medical technology company’s stock valued at $12,309,000 after buying an additional 1,150,669 shares in the last quarter. Driehaus Capital Management LLC purchased a new stake in shares of Alphatec during the 1st quarter valued at about $10,398,000. Finally, Motley Fool Wealth Management LLC purchased a new stake in shares of Alphatec during the 1st quarter valued at about $9,070,000. 66.35% of the stock is currently owned by institutional investors.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.